ArticleThe Journal of clinical investigation2019
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Article in The Journal of clinical investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Genomic characterization of rabies virus glycoprotein co-expressing CD70 CAR-T cells during killing of glioma cellsFrontiers in immunology · 2026Article
- Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution.Journal of hematology & oncology · 2025Review
- Computational structural optimization enhances IL13Rα2 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Bibliometric analysis of the top 100 most cited articles on the immunotherapy for glioblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?Current treatment options in oncology · 2024Review
- Cellular Therapy in NSCLC: Between Myth and Reality.Current oncology reports · 2023Review
- CAR-T Cells for the Treatment of Lung Cancer.Life (Basel, Switzerland) · 2022Review
- Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review.Frontiers in oncology · 2022Review
- Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor ß towards B-Acute Myeloid Leukaemia Blasts.Cell journal · 2021Article
- Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma.Journal of hematology & oncology · 2021Review
- Review
- Engineering precision therapies: lessons and motivations from the clinic.Synthetic biology (Oxford, England) · 2021Review
- Blood-Brain Barrier, Cell Junctions, and Tumor Microenvironment in Brain Metastases, the Biological Prospects and Dilemma in Therapies.Frontiers in cell and developmental biology · 2021Review
- CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?Molecular therapy : the journal of the American Society of Gene Therapy · 2020Review
- Glioblastoma Immune Landscape and the Potential of New Immunotherapies.Frontiers in immunology · 2020Review
- CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens.Frontiers in immunology · 2020Review
Corrections and comments
- ExpressionOfConcernFor
Authors and funding
21 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.